• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

9.250 -1.750 (-15.91%)
Delayed Quote Updated: 3:51 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,851
Open 9.400
Bid (Size) 0.9250 (100)
Ask (Size) 37.00 (100)
Prev. Close 11.00
Today's Range 9.250 - 9.400
52wk Range 9.000 - 30.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Performance

52-Week Range 69.6% below 52-week high
9.250
9.0052W Low 30.4552W High
1 Week 15.9% below 1-week high
9.251W Low 11.001W High

NewAmsterdam Pharma Company N.V. - Warrant (NAMSW) traded between $9.00 and $30.45 over the past 52 weeks and last traded at $9.25, 69.6% below its 52-week high. Over the past week it ranged between $9.25 and $11.00.

Past 12 Months
-14.0%
-18.9%
-51.3%
-51.6%
-60.0%
-66.1%
1W -$1.50
1M -$2.15
3M -$9.75
6M -$9.85
YTD -$13.85
1Y -$18.05

NAMSW was -66.1% over the past year, -51.6% over six months, -60.0% year to date, -14.0% in the last week.

12 Months vs Market
NAMSW
-66.1%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months NAMSW returned -66.1% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 1.30× 3-mo avg
Today 1,851 3-mo avg 1.4K
1W
872.0
1M
349.0
3M
1.4K
6M
1.4K
YTD
1.0K
1Y
1.0K

NAMSW most recently traded 1,851 shares against a 3-month average daily volume of 1.4K.

More News

Read More
News headline image
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
September 02, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
August 26, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 05, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 24, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
July 01, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
June 03, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 28, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
May 11, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 07, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
March 23, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
February 18, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 04, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Warrant publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Warrant is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Warrant trade on?
NewAmsterdam Pharma Company N.V. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant is NAMSW on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Warrant?
The current price of NewAmsterdam Pharma Company N.V. - Warrant is 9.250
When was NewAmsterdam Pharma Company N.V. - Warrant last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Warrant was at 10/23/26 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap